NYMOX PHARMACEUTICAL CORP

Nymox Pharmaceutical Corporation is a biotechnology company that engages in the research and development of therapeutic drug candidates and diagnostic test products. The company focuses primarily on treatments for enlarged prostate conditions, specifically benign prostatic hyperplasia. Its core drug candidate under development is fexapotide triflutate, also designated as NX-1207. Nymox also offers reference laboratory services. The company's target end users and customers include elderly patients requiring treatments for prostate conditions, medical doctors, and institutional healthcare customers such as multi-hospital alliances and healthcare providers.

The company maintains operational offices in the Bahamas, the United States, and Canada, while coordinating clinical and regulatory activities across international markets, including the United Kingdom and Denmark. It also maintains hundreds of patents and patent applications globally, spanning jurisdictions such as Australia, China, Japan, New Zealand, South Korea, Canada, the United States, and Europe. The principal executive offices and corporate headquarters of Nymox are located in Nassau, The Bahamas.

Summary of the business section of Nymox Pharmaceutical's latest annual report, written by StockData.

“Laurent, Hasbrouck Heights and Orange Country offices, as at December 31, 2021, the Corporation employed three persons in research and development, and one of them also responsible for administration.”